Author Affiliations: Johns Hopkins University School of Medicine, Baltimore, Md.
Approaches to the treatment of human immunodeficiency virus type 1 (HIV-1)
infection continue to evolve rapidly, raising complex medical and scientific
questions. The advent of highly active antiretroviral therapy (HAART), involving
combinations of inhibitors of HIV-1 reverse transcriptase and protease, has
resulted in dramatic decreases in death rates from acquired immunodeficiency
syndrome (AIDS) in the United States.1 In select
patient populations participating in clinical trials of various HAART regimens,
clearance of detectable virus from blood is observed in 70% to 90% of patients.2- 4 Patients who respond
to HAART show a surprising degree of reconstitution of the immune system.
Blankson J, Siliciano RF. Interleukin 2 Treatment for HIV Infection. JAMA. 2000;284(2):236-238. doi:10.1001/jama.284.2.236